Why is 8011 alloy preferred for pharmaceutical blister packs?
8011 offers superior formability with 25-30% elongation for deep-drawn cavities. Its high purity (99.3% Al) meets FDA 21 CFR requirements for drug contact. The alloy's Fe/Si composition prevents pinhole defects during foil rolling. It maintains barrier properties against moisture and oxygen permeation. Typical thickness ranges from 20-50μm for optimal protection.
How does 8011 compare to 8021 for blister packaging?
8011 has 15% higher tensile strength (145MPa vs 125MPa in 8021) for better puncture resistance. Both alloys share similar corrosion resistance in pH 4-8 environments. 8011's slightly higher iron content improves heat seal consistency at 180-220°C. 8021 is preferred for ultra-thin (<15μm) applications due to lower hardness. EU Pharmacopeia approves both for sterile packaging.
What surface treatments enhance 8011's pharmaceutical performance?
Electrochemical polishing reduces surface roughness to <0.8μm Ra for cleanability. Chromate-free passivation (e.g., TCPO) improves corrosion resistance. PVdC or acrylic lacquer coatings enable cold-form blister processing. Laser etching creates micro-textures for improved lidding adhesion. All treatments must pass ISO 10993-1 biocompatibility tests.
What are the key quality tests for 8011 blister foil?
Pinhole inspection requires <3 defects/m² under 2000lx backlighting. Thickness tolerance must be ±5% across rolls. Residual solvents are limited to <2mg/m² per USP <661>. Burst strength exceeds 1.5kPa for 40μm foil. DSC analysis verifies thermal stability up to 300°C.
How does 8011 support sustainability in pharma packaging?
Its 100% recyclability aligns with WHO's AMR packaging guidelines. Foil production consumes 60% less energy than plastic alternatives. Lightweighting to 25μm reduces material use by 20% versus legacy 50μm. Post-consumer recycled content can reach 30% without performance loss. Lifecycle assessments show 45% lower carbon footprint than multi-layer plastics.
